Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: Secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial

Archives of Neurology

Volumn 68, Issue 10, 2011, Pages 1245-1251

  Callahan, Alfred ^a   Amarenco, Pierre ^c   Goldstein, Larry B ^d   Sillesen, Henrik ^e   Messig, Mike ^f   Samsa, Gregory P ^d   Altafullah, Irfan ^g   Ledbetter, Lucy Y ^b   MacLeod, Mary J ^h   Scott, Russell ⁱ   Hennerici, Michael ^j   Zivin, Justin A ^k   Welch, K Michael A ^l  

^a VANDERBILT UNIVERSITY   (United States)

^b Neurology Center of Middle Tennessee   (United States)

^c INSERM   (France)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f PFIZER INC   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF ABERDEEN   (United Kingdom)

ⁱ CHRISTCHURCH HOSPITAL   (New Zealand)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR PHYSIOLOGICAL PROCESSES; CHOLESTEROL; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PYRROLES; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; TRIGLYCERIDES; YOUNG ADULT;

EID: 80053917726     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.146     Document Type: Article

References (26)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434-444. (Pubitemid 23046633)
2. Tuomilehto J, Rastenyte D, Jousilahti P, Sarti C, Vartiainen E. Diabetes mellitus as a risk factor for death from stroke: prospective study of the middle-aged Finnish population. Stroke. 1996;27(2):210-215. (Pubitemid 26044488)
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234. (Pubitemid 28350165)
4. Wannamethee SG, Perry IJ, Shaper AG. Nonfasting serum glucose and insulin concentrations and the risk of stroke. Stroke. 1999;30(9):1780-1786. (Pubitemid 29411814)
5. Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D'Agostino RB, Wolf PA. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med. 2006;166(1):106-111. (Pubitemid 43063849)
6. Li W, Ma D, Liu M, et al. Association between metabolic syndrome and risk of stroke: a meta-analysis of cohort studies. Cerebrovasc Dis. 2008;25(6):539-547. (Pubitemid 351861472)
7. Boden-Albala B, Sacco RL, Lee HS, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke. 2008;39(1):30-35.
8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913. (Pubitemid 35472129)
9. Labreuche J, Touboul PJ, Amarenco P. Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies. Atherosclerosis. 2009;203(2):331-345.
10. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis. 2008;196(2):489-496. (Pubitemid 351146660)
11. Amarenco P, Goldstein LB, Callahan A III, et al SPARCL Investigators. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis. 2009;204(2):515-520.
12. Suk SH, Sacco RL, Boden-Albala B, et al Northern Manhattan Stroke Study. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2003;34(7):1586-1592. (Pubitemid 36842606)
13. Ovbiagele B, Saver JL, Lynn MJ, Chimowitz M; WASID Study Group. Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. Neurology. 2006;66(9):1344-1349. (Pubitemid 43739642)
14. Iglseder B, Cip P, Malaimare L, Ladurner G, Paulweber B. The metabolic syndrome is a stronger risk factor for early carotid atherosclerosis in women than in men. Stroke. 2005;36(6):1212-1217. (Pubitemid 40798741)
15. McNeill AM, Rosamond WD, Girman CJ, et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (the ARIC Study). Am J Cardiol. 2004;94(10):1249-1254. (Pubitemid 39469942)
16. Kearney PM, Blackwell L, Collins R, et al Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-125.
17. Amarenco P, Bogousslavsky J, Callahan A III, et al Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559. (Pubitemid 44202151)
18. Amarenco P, Bogousslavsky J, Callahan AS, et al SPARCL Investigators. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovasc Dis. 2003;16(4):389-395.
19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-553. (Pubitemid 28319935)
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
21. Grundy SM, Cleeman JI, Daniels SR, et al American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published corrections appear in Circulation. 2005;112(17):e297 and Circulation. 2005;112(17):e298]. Circulation. 2005;112(17):2735-2752. (Pubitemid 41532612)
22. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366(9491):1059-1062. (Pubitemid 41338752)
23. Rothwell PM. Treating individuals 2: subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365(9454):176-186. (Pubitemid 40091809)
24. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol. 2004;57(3):229-236. (Pubitemid 38456874)
25. Deedwania P, Barter P, Carmena R, et al Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368(9539):919-928. (Pubitemid 44331360)
26. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.